Safety assessment of botanicals and botanical preparations used as ingredients in food supplements: Testing an European food safety authority-tiered approach

Molecular Nutrition and Food Research

Volumn 54, Issue 2, 2010, Pages 175-185

  Speijers, Gerrit ^a   Bottex, Bernard ^b   Dusemund, Birgit ^c   Lugasi, Andrea ^d   Tóth, Jaroslav ^e   Amberg Müller, Judith ^f   Galli, Corrado L ^g   Silano, Vittorio ^h   Rietjens, Ivonne M C M ⁱ  

^a General Health Effects Toxicology Safety Food (GETS)   (Netherlands)

^b EUROPEAN FOOD SAFETY AUTHORITY   (Italy)

^c FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^d National Institute of Food Hygiene and Nutrition Budapest   (Hungary)

^e Physics and Informatics   (Slovakia)

^f FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^g UNIVERSITY OF MILAN   (Italy)

^h Medicine of Migration National Institute for Migrant Health and Poverty   (Italy)

ⁱ WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Botanical preparations; Botanicals; Guidance; Safety assessment

Indexed keywords

PLANT EXTRACT; PLANT MEDICINAL PRODUCT;

ANIMAL; CHEMISTRY; DIET SUPPLEMENTATION; HUMAN; METHODOLOGY; POLLUTANT; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW; SAFETY; SPECIES DIFFERENCE; STANDARD; TOXICITY TESTING; TOXICOLOGY;

ANIMALS; CONSUMER PRODUCT SAFETY; DIETARY SUPPLEMENTS; ENVIRONMENTAL POLLUTANTS; GUIDELINES AS TOPIC; HUMANS; PLANT EXTRACTS; PLANT PREPARATIONS; QUALITY CONTROL; SPECIES SPECIFICITY; TOXICITY TESTS; TOXICOLOGY;

EID: 76749140967     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200900240     Document Type: Review

References (75)

1. Scientific Committee of the European Food Safety Authority, Discussion paper on ''botanicals and botanical preparations widely used as food supplements and related products: coherent and comprehensive risk assessment and consumer information approaches''. Brussel 2004, pp. 1-6.
2. EFSA (European Food Safety Authority), Guidance on safety assessment of botanicals and botanical preparations intended for use as ingredients in food supplements, 2009.
3. Peterson, R. K., Shama, L. M., A comparative risk assessment of genetically engineered, mutagenic, and conventional wheat production systems. Transgenic Res. 2005, 14, 859-875.
4. EFSA (European Food Safety Authority), Guidance document of the Scientific Panel on Genetically Modified Organisms for the risk assessment of genetically modified plants and derived food and feed. EFSA J. 2006, 99, 1-100.
5. Regulation (EC) 1829/2003 on GM food and feed, and Directive 2001/18/EC on the release of GMOs into the environment.
6. Spaenij-Dekking, L., Kooy-Winkelaar, Y., Van Veelen, P., Drijfhout, J. W. et al., Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology 2005, 129, 797-806.
7. Zhou, K., Su, L., Yu, L. L., Phytochemicals and antioxidant properties in wheat bran. J. Agric. Food Chem. 2004, 52, 6108-6114.
8. Zhou, K., Yu, L., Antioxidant properties of bran extracts from Trego wheat grown at different locations. J. Agric. Food Chem. 2004, 52, 1112-1117.
9. Jenkins, D., Kendall, C., Vuksan, V., Augustin, L. et al., The effect of wheat bran particle size on laxation and colonic fermentation. J. Am. Col. Nutr. 1999, 18, 339-345.
10. Council Regulation (EEC) N1 315/93 of 8 April 1993 laying down Community procedures for contaminants in food. Off. J. Eur. Union L 37, 13.2.1993, p. 1.
11. WHO, Selected mycotoxins: ochratoxins, trichothecenes, ergot. Environ. Health Crit., 1990, 105, 263.
12. Mueller, H. M., Metzger, K. U., Modi, R., Reimann, J., Ergosterol and fusarium toxins in wheat bran and wheat. J. Anim. Physiol. Anim. Nutr. 1994, 71, 48-55.
13. Visconti, A., Haidukowski, E. M., Michelangelo Pascale, M., Silvestri, M., Reduction of deoxynivalenol during durum wheat processing and spaghetti cooking. Toxicol. Lett. 2004,153,181-189.
14. Codex Alimentarius 1995 Codex standard for Wheat and Durum Wheat, CODEX STAN 199-1995.
15. Codex Alimentarius 2003 Code of practice for the prevention and reduction of mycotoxin contamination in cereals, including annexes on ochratoxin a, zearalenone, fumonisins and tricothecenes. CAC/RCP 51-2003: 1-8.
16. Brera, C., Catano, C., De Santis, B., Debegnach, F. et al., Effect of industrial processing on the distribution of aflatoxins and zearalenone in corn-milling fractions. J. Agri. Food Chem. 2006, 54, 5014-5019.
17. Brera, C., Debegnach, F., Grossi, S., Miraglia, M., Effect of industrial processing on the distribution of fumonisin B-1 in dry milling corn fractions. J. Food Protec. 2004, 67, 1261-1266.
18. Broggi, L. E., Resnik, S. L., Pacin, A. M., González, H. H. L. et al., Distribution of fumonisins in dry-milled corn fractions in Argentina. Food Add. Contam. 2002, 19, 465-469.
19. Ryu, D., Jackson, L. S., Bullerman, L. B., Effects of processing on zearalenone. Mycotoxins Food Safety 2002, 504, 205-216.
20. Trigo Stockli, D. M., Deyoe, C. W., Satumbaga, R. F., Pedersen, J. R., Distribution of deoxynivalenol and zear-alenone in milled fractions of wheat. Cereal Chem.1996, 73, 388-391.
21. Rafai, P., Bata, A., Jakab, L., Vanyi, A., Evaluation of mycotoxin-contaminated cereals for their use in animal feeds in Hungary. Food Add. Contam. 2000, 17, 799-808.
22. Gardana, C., Nalin, F., Simonetti, P., Evaluation of flavonoids and furanocoumarins from Citrus bergamia (bergamot) juice and identification of new compounds. Molecules 2008,13,2220-2228.
23. Avula, B., Upparapalli, S. K., Navarrete, A., Khan, I. A., Simultaneous quantification of adrenergic amines and flavonoids in C. aurantium, various Citrus species, and dietary supplements by liquid chromatography. J. AOAC Intern. 2005, 88, 1593-1606.
24. Fugh-Berman, A., Myers, A., Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp. Biol. Med. 2004,229,698-704.
25. Haaz, S., Fontaine, K. R., Cutter, G., Limdi, N. et al., Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obesity Rev. 2006, 7, 79-88.
26. Calapai, G., Firenzuoli, F., Saitta, A., Squadrito, F. et al., Antiobesity and cardiovascular toxic effects of Citrus aurantium extracts in the rat: a preliminary report. Fitoter-apia 1999, 70, 586-592.
27. Jack, S., Desjarlais-Renaud, T., Pilon, K., Bitter orange or synephrine: update on cardiovascular adverse reactions. Can. Adverse React. Newsl. 2007, 17, 2-3.
28. Avula, B., Upparapalli, S. K., Khan, I. A., Simultaneous analysis of adrenergic amines and flavonoids in Citrus peel jams and fruit juices by liquid chromatography: Part 2. J. AOAC Intern. 2007, 90, 633-640.
29. Pellati, F., Benvenuti, S., Melegari, M., Firenzuoli, F., Determination of adrenergic agonists from extracts and herbal products of Citrus aurantium L. var. amara by LC. J. Pharmac. Biomed. Anal. 2002, 29, 1113-1119.
30. Pellati, F., Benvenuti, S., Chromatographic and electro-phoretic methods for the analysis of phenethylamine alkaloids in Citrus aurantium. J. Chromatog. A 2007, 1161, 71-88.
31. NTP/NIEHS, Bitter orange (Citrus aurantium var. amara) extracts and constituents (7)-p-synephrine [CAS No. 94-07-5] and (7)-p-octopamine [CAS No. 104-14-3]. Review of toxicological literature. National Toxicology Program (NTP), National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, US Department of Health and Human Services, Research Triangle Park, North Carolina, 2004.
32. Blumenthal, M., Bitter orange peel and synephrine: Part 1 & Part 2. Herbal Gram 2005, 66, 0 (web-only exclusive).
33. Gaglia, C. A., Jr., Phenylephrine hydrochloride. Analyt. Prof. Drug Subst. 1974, 3, 483-512.
34. Allison, D. B., Cutter, G., Poehlman, E. T., Moore, D. R., Barnes, S., Exactly which synephrine alkaloids does Citrus aurantium (bitter orange) contain? Intern. J. Obes. 2005, 29, 443-446.
35. Santana, J., Sharpless, K. E., Nelson, B. C., Determination of para-synephrine and meta-synephrine positional isomers in bitter orange-containing dietary supplements by LC/UV and LC/MS/MS. Food Chem. 2008, 109, 675-682.
36. AFSSAPS, Agence Francaise de Sécurité Sanitaire des Produits de Santé, Communiqué de Presse. Suspension de l'autorisation de mise sur le marché de la spé cialité pharmaceutique EXOLISEs (gallate d'é pigallocaté chol), 2003.
37. Sarma, D. N., Barrett, M. L., Chavez, M. L., Gardiner, P. et al., Safety of green tea extracts. A systematic review by the US pharmacopeia. Drug Safety 2008, 31, 469-484.
38. Isbrucker, R. A., Edwards, J. A., Wolz, E., Davidovich, A., Bausch, J., Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem. Toxicol. 2006, 44, 636-650.
39. USDA database for the flavonoid content of selected foods, US Department of Agriculture, Agricultural Research Service, 2007.
40. Kantelip, J. P., Laroche, D., Green tea and liver disorders. National Drug Surveillance survey submitted to the Technical Committee. Besancon: Besancon regional drug surveillance centre, February 11, 2003.
41. Canadian Adverse Reaction Newsletter Green tea extract (Green Lite): suspected association with hepatotoxicity. 2007, vol. 17/1:3.
42. Chen, L., Lee, M-J., Li, H., Yang, C. C., Absorption, distribution, and elimination of tea polyphenols in rats. Drug Metab. Dispos. 1997, 25, 1045-1050.
43. Johnson, W. D., Morrissey, R. L., Crowell, J. A., McCormick, D. L., Subchronical oral toxicity of green tea polyphenols in rats and dogs. The Toxicologist 1999, 48, 57-58.
44. Chow, H. H., Hakim, I. A., Vining, D. R., Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. Clin. Cancer Res. 2005, 11, 4627-4633.
45. European Pharmacopoeia, Fennel, Bitter - Foeniculi amari fructus. Council of Europe (5th edn.), 2005, 01/2005:0824.
46. Council of Europe, Active principles (constituents of toxicological concern) contained in natural sources of flavourings. Approved by the Committee of Experts on Flavouring Substances, October 2005, Health Protection of the Consumer Series. Council of Europe Press, Strasbourg, 2006.
47. SCF, Opinion of the Scientific Committee on Food on estragole (1-allyl-4-methoxybenzene), 2001.
48. EFSA, Opinion of the scientific committee on a request from EFSA related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic. 2005.
49. Miller, E. C., Swanson, A. B., Phillips, D. H., Fletcher, T. L. et al., Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer Res. 1983, 43, 1124-1134.
50. I. M. C. M., Punt, A., Schilter, B., Scholz, G. et al., Insilico methods for physiologically based biokinetics (PBBK) models describing bioactivation and detoxification of coumarin and estragole; implications for risk assessment. Mol. Nutr. Food Res. 2009, 54, this issue, DOI: 10.1002/200900240.
51. JECFA, trans-Anethole (addendum), in: Safety Evaluation of Certain Food Additives, prepared by the 51st meeting of JECFA, FAS 42-JECFA 51/5, 1998, pp. 5-32.
52. Jeurissen, S. M. F., Punt, A., Delatour, Th., Rietjens, I. M. C. M., Basil extract inhibits the sulfotransferase mediated formation of DNA aducts of the procarcinogen 10-hydroxyestragole by rat and human liver S9 homogenates and in HepG2 human hepatoma cells. Food Chem. Toxicol. 2008, 46,2296-2302.
53. Ahmed, M., Khan, M. Y., Khan, A. A., Effects of Ocimum sanctum (Tulsi) on the reproductive system, an updated review. Biomed. Res. 2002, 13, 63-67.
54. Ahmed, M., Ahamed, N., Aladakatti, R. H., Ghosesawar, M. G., Reversible anti-fertility effect of benzene extract of Ocimum sanctum leaves on sperm parameters and fructose content in rats. J. Basic Clin. Physiol. Pharmacol. 2002, 13, 51-59.
55. Reghunandan, R., Sood, S., Reghunandan, V., Arora, B. B. et al., Effects of feeding Ocimum sanctum (Tulsi) leaves on fertility in rabbits. Biomed. Res. Aligarh 1997, 8, 187-191.
56. SCF, Opinion of the Scientific Committee on Food on methyleugenol (4-allyl-1,2-dimethoxybenzene), 2001.
57. WHO, Folium Ocimi Sancti, WHO monographs on selected medicinal plants, vol. 2, World Health Organization, Geneva, Switzerland 2002, pp. 206-216.
58. Blaschek, W., Hänsel, R., Keller, K., Reichling, J. et al. (Eds.), Hager's Handbuch der pharmazeutische Praxis. Folgeband 2: Drogen A-K (5th edn.), Springer, Berlin, Germany 1998.
59. Lal, R. N., Sen, T. K., Nigam, M. C., Gas chromatography of the essential oil of Ocimum sanctum L. Parf umerie Kosmetiks 1978, 59, 230-231.
60. Rietjens, I. M. C. M., Slob, W., Galli, C., Silano, V., Risk assessment of botanicals and botanical preparations intended for use in food and food supplements: emerging issues. Toxicol. Lett. 2008, 180, 131-136.
61. Thompson, L. U., Robb, P., Serraino, M., Cheung, F., Mammalian lignan production from various foods. Nutr. Cancer 1991, 16, 43-52.
62. Smeds, A. I., Eklund, P. C., Sjholm, R. E., Willför, S. M. et al., Quantification of a broad spectrum of lignans in cereals, oilseeds, and nuts. J. Agric. Food. Chem. 2007, 55, 1337-1346.
63. Milder, I. E. J., Arts, I. C. W., Van de Putte, B., Venema, D. P., Hollman, P. C. H., Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol, and matairesinol. Br. J. Nutr. 2005, 93, 393-402.
64. Adlercreutz, H., Phyto-oestrogens and cancer. Lancet Oncol. 2002,3,364-373.
65. Hutchins, A. M., Martini, M. C., Olson, B. A., Thomas, W., Slavin, J. L., Flaxseed consumption influences endogenous hormone concentrations in postmenopausal women. Nutr. Cancer 2001, 39, 58-65.
66. Phipps, W. R., Martini, M. C., Lampe, J. W., Slavin, J. L., Kurzer, M. S., Effect of flax seed ingestion on the menstrual cycle. J. Clin. Endocrinol. Metab. 1993, 77, 1215-1219.
67. Kurzer, M. S., Lampe, J. W., Martini, M. C., Adlercreutz, H., Fecal lignan and isoflavonoid excretion in premenopausal women consuming flaxseed powder. Cancer Epidemiol. Biomarkers Prev. 1995, 4, 353-358.
68. Thompson, L. U., Chen, J. M., Li, T., Strasser-Weippl, K., Goss, P. E., Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Canada Clin. Cancer Res. 2005,11,3828-3835.
69. Dodin, S., Lemay, A., Jacques, H., Legare, F. et al., The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J. Clin. Endocrin. Metab. 2005, 90, 1390-1397.
70. Adlercreutz, H., Hoeckerstedt, K., Bannwart, C., Bloigu, S. et al., Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). J. Steroid Biochem. 1987, 27, 1135-1144.
71. Adlercreutz, H., Does fiber-rich food containing animal lignan precursors protect against both colon and breast cancer? An extension of the ''fiber hypothesis''. Gastro-enterology 1984, 86, 761-764.
72. Vanherweghem, J.-L., Depierreux, M., Tielemans, C., Abramowicz, D. et al., Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993, 341, 387-391.
73. Vanhaelen, M., Vanhaelen-Fastre, R., But, P., Vanherweghem, J.-L., Identification of aristolochic acid in Chinese herbs. Lancet 1994, 343, 174.
74. Oudesluys-Murphy, A. M., Oudesluys, N., Tea: not immoral, illegal, or fattening, but is it innocuous? Lancet 2002, 360, 878.
75. Johanns, E. S. D., van der Kolk, L. E., van Gemert, H. M. A., Sijben, A. E. et al., An epidemic of epileptic seizures after consumption of herbal tea. Ned. Tijdschr. Geneesk. 2002, 146,813-816.